Association Between Glycolysis Markers and Prognosis of Liver Cancer: a Systematic Review and Meta-analysis

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2023 Dec 20

PMID 38114977

Authors

Boqin Wang

Rong Pu

Affiliations

Soon will be listed here.

Abstract

Background: In recent years, the capacity of tumor cells to maintain high levels of glycolysis, even in the presence of oxygen, has emerged as one of the main metabolic traits and garnered considerable attention. The purpose of this meta-analysis is to investigate the prognostic value of glycolysis markers in liver cancer.

Methods: PubMed, Embase, and Cochrane Library databases were searched for articles on glycolytic marker expression levels associated with the prognosis of liver cancer until April 2023. Stata SE14.0 was used to calculate the aggregate hazard ratios and 95% confidence intervals.

Results: Thirty-five studies were included. The worse overall survival (OS) (P < 0.001), disease-free survival (DFS) (P = 0.001), recurrence-free survival (RFS) (P = 0.004), and time to recurrence (TTR) (P < 0.001) were significantly associated with elevated expression of glycolysis markers. Higher expression of PKM2 (P < 0.001), STMN1 (P = 0.002), MCT4 (P < 0.001), GLUT1 (P = 0.025), HK-2 (P < 0.001), and CA9 (P < 0.001) were significantly related to shorter OS. Increased levels of PKM2 (P < 0.001), CA9 (P = 0.005), and MCT4 (P < 0.001) were associated with worse DFS. Elevated PKM2 expression (P = 0.002) was also associated with poorer RFS in hepatocellular carcinoma patients. GLUT2 expression was not correlated with the prognosis of liver cancer (P = 0.134).

Conclusions: Elevated expression of glycolysis markers was associated with worse OS, DFS, RFS, and TTR in patients with liver cancer. Therefore, these glycolysis markers could serve as potential prognostic markers and therapeutic targets in liver cancer.

Trial Registration: PROSPERO registration: CRD42023469645.

Citing Articles

Tracking fructose 1,6-bisphosphate dynamics in liver cancer cells using a fluorescent biosensor.

Perez-Chavez I, Koberstein J, Malo Pueyo J, Gilglioni E, Vertommen D, Baeyens N iScience. 2024; 27(12):111336.

PMID: 39640569 PMC: 11617404. DOI: 10.1016/j.isci.2024.111336.

Diagnostic lncRNA high expression for liver patients prognosis and medication guidance: a systematic review and meta-analysis.

Zhu H, Chen H, Zhu X, Zhang B, Jin C Front Pharmacol. 2024; 15:1462512.

PMID: 39211780 PMC: 11357924. DOI: 10.3389/fphar.2024.1462512.

Identification of vitamin D-related signature for predicting the clinical outcome and immunotherapy response in hepatocellular carcinoma.

Wang T, Han L, Xu J, Guo B Medicine (Baltimore). 2024; 103(19):e37998.

PMID: 38728505 PMC: 11081612. DOI: 10.1097/MD.0000000000037998.

References

Lis P, Dylag M, Niedzwiecka K, Ko Y, Pedersen P, Goffeau A . The HK2 Dependent "Warburg Effect" and Mitochondrial Oxidative Phosphorylation in Cancer: Targets for Effective Therapy with 3-Bromopyruvate. Molecules. 2016; 21(12). PMC: 6273842. DOI: 10.3390/molecules21121730. View

Avril N, Menzel M, Dose J, Schelling M, Weber W, Janicke F . Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med. 2001; 42(1):9-16. View

Huang Y, Xian L, Liu Z, Wei L, Qin L, Xiong Y . AMPKα2/HNF4A/BORIS/GLUT4 pathway promotes hepatocellular carcinoma cell invasion and metastasis in low glucose microenviroment. Biochem Pharmacol. 2022; 203:115198. DOI: 10.1016/j.bcp.2022.115198. View

Sohn W, Lee H, Lee S, Lim J, Lee M, Park C . Obesity and the risk of primary liver cancer: A systematic review and meta-analysis. Clin Mol Hepatol. 2020; 27(1):157-174. PMC: 7820201. DOI: 10.3350/cmh.2020.0176. View

Iansante V, Choy P, Fung S, Liu Y, Chai J, Dyson J . PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation. Nat Commun. 2015; 6:7882. PMC: 4918319. DOI: 10.1038/ncomms8882. View

Chen R, Zhou X, Yu Z, Liu J, Huang G . Low Expression of LDHB Correlates With Unfavorable Survival in Hepatocellular Carcinoma: Strobe-Compliant Article. Medicine (Baltimore). 2015; 94(39):e1583. PMC: 4616837. DOI: 10.1097/MD.0000000000001583. View

Byun J, Choi Y, Kang Y, Jang B, Kang K, Jeon Y . Retinoic acid-related orphan receptor alpha reprograms glucose metabolism in glutamine-deficient hepatoma cells. Hepatology. 2014; 61(3):953-64. DOI: 10.1002/hep.27577. View

Liu W, Tian M, Yang L, Lin Y, Jin L, Ding Z . PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma. Oncotarget. 2014; 6(2):846-61. PMC: 4359260. DOI: 10.18632/oncotarget.2749. View

Kim Y, Jeong D, Pak K, Han M, Kim J, Liangwen L . SLC2A2 (GLUT2) as a novel prognostic factor for hepatocellular carcinoma. Oncotarget. 2017; 8(40):68381-68392. PMC: 5620264. DOI: 10.18632/oncotarget.20266. View

10.

Xu Q, Tu J, Dou C, Zhang J, Yang L, Liu X . HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma. Mol Cancer. 2017; 16(1):178. PMC: 5738801. DOI: 10.1186/s12943-017-0748-y. View

11.

Muramatsu T, Miyauchi T . Basigin (CD147): a multifunctional transmembrane protein involved in reproduction, neural function, inflammation and tumor invasion. Histol Histopathol. 2003; 18(3):981-7. DOI: 10.14670/HH-18.981. View

12.

Xu D, Liang J, Lin J, Yu C . PKM2: A Potential Regulator of Rheumatoid Arthritis via Glycolytic and Non-Glycolytic Pathways. Front Immunol. 2020; 10:2919. PMC: 6930793. DOI: 10.3389/fimmu.2019.02919. View

13.

Hsu P, Sabatini D . Cancer cell metabolism: Warburg and beyond. Cell. 2008; 134(5):703-7. DOI: 10.1016/j.cell.2008.08.021. View

14.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

15.

Clower C, Chatterjee D, Wang Z, Cantley L, Vander Heiden M, Krainer A . The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc Natl Acad Sci U S A. 2010; 107(5):1894-9. PMC: 2838216. DOI: 10.1073/pnas.0914845107. View

16.

Chen Y, Yang H, Chen S, Lu Z, Li B, Jiang T . SIRT1 regulated hexokinase-2 promoting glycolysis is involved in hydroquinone-enhanced malignant progression in human lymphoblastoid TK6 cells. Ecotoxicol Environ Saf. 2022; 241:113757. DOI: 10.1016/j.ecoenv.2022.113757. View

17.

Ohno A, Yorita K, Haruyama Y, Kondo K, Kato A, Ohtomo T . Aberrant expression of monocarboxylate transporter 4 in tumour cells predicts an unfavourable outcome in patients with hepatocellular carcinoma. Liver Int. 2014; 34(6):942-52. DOI: 10.1111/liv.12466. View

18.

Kang H, Kim I, Sung C, Shim J, Yu E . Expression of carbonic anhydrase 9 is a novel prognostic marker in resectable hepatocellular carcinoma. Virchows Arch. 2015; 466(4):403-13. DOI: 10.1007/s00428-014-1709-0. View

19.

Hsieh S, Huang S, Yu M, Yeh T, Chen T, Lin Y . Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma. Mol Carcinog. 2010; 49(5):476-87. DOI: 10.1002/mc.20627. View

20.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View